AA
RAPP

AlphaCentric Advisors’s Rapport Therapeutics RAPP Stock Holding History

AlphaCentric Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Buy
6,438
+408
+7% +$11.5K 0.2% 142
2025
Q4 		$183K Buy
+6,030
New +$167K 0.18% 153

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $401M AUM 284.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

AlphaCentric Advisors's RAPP Position: Q1 2026 in Review

AlphaCentric Advisors increased its Rapport Therapeutics (RAPP) stake by 6.8% in Q1 2026, buying an estimated $11.5K and bringing the position to 6,438 shares worth $201K. The position accounts for 0.2% of the portfolio, ranked #142.

AlphaCentric Advisors first reported a position in RAPP in Q4 2025 and has held it in 2 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • AlphaCentric Advisors held 6,438 shares of Rapport Therapeutics worth $201K as of Q1 2026.
  • AlphaCentric Advisors bought 408 Rapport Therapeutics shares in Q1 2026, an estimated $11.5K.
  • Rapport Therapeutics made up 0.2% of AlphaCentric Advisors's portfolio in Q1 2026, its #142 holding.
  • AlphaCentric Advisors first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on AlphaCentric Advisors's 13F filing for Q1 2026, filed 7 May 2026.